Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glen R Hanson

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Science & Practice Perspectives|June 24, 2008
Two perspectives, one goalGlen R Hanson
Drug and Alcohol Dependence|February 16, 2010
NIDA 35-year anniversary: Past lessons, present accomplishments and future challenges (2001-2003)Glen R Hanson
JAMA|February 25, 2003
Public health implications of excessive alcohol consumptionGlen R Hanson, Ting-Kai Li
European Journal of Pharmacology|November 13, 2003
Impact of psychostimulants on vesicular monoamine transporter functionAnnette E Fleckenstein, Glen R Hanson
Journal of Substance Abuse Treatment|September 11, 2002
Putting drug abuse research to use in real-life settingsGlen R Hanson, Alan I Leshner, Betty Tai
Neuropharmacology|July 30, 2008
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implicationsAnnette E Fleckenstein, Trent J Volz, Glen R Hanson
Journal of Neurochemistry|January 26, 2007
The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficitsTrent J Volz, Glen R Hanson, Annette E Fleckenstein
Annals of the New York Academy of Sciences|November 11, 2008
Differential response of neurotensin to methamphetamine self-administrationPaul S Frankel, Amanda J Hoonakker, Glen R Hanson
European Journal of Pharmacology|July 10, 2007
Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2Evan L Riddle, Glen R Hanson, Annette E Fleckenstein
Life Sciences|August 6, 2013
Bath salts and synthetic cathinones: an emerging designer drug phenomenonChristopher L German, Annette E Fleckenstein, Glen R Hanson
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Science & Practice Perspectives|June 24, 2008
Two perspectives, one goalGlen R Hanson
Drug and Alcohol Dependence|February 16, 2010
NIDA 35-year anniversary: Past lessons, present accomplishments and future challenges (2001-2003)Glen R Hanson
JAMA|February 25, 2003
Public health implications of excessive alcohol consumptionGlen R Hanson, Ting-Kai Li
European Journal of Pharmacology|November 13, 2003
Impact of psychostimulants on vesicular monoamine transporter functionAnnette E Fleckenstein, Glen R Hanson
Journal of Substance Abuse Treatment|September 11, 2002
Putting drug abuse research to use in real-life settingsGlen R Hanson, Alan I Leshner, Betty Tai
Neuropharmacology|July 30, 2008
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implicationsAnnette E Fleckenstein, Trent J Volz, Glen R Hanson
Journal of Neurochemistry|January 26, 2007
The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficitsTrent J Volz, Glen R Hanson, Annette E Fleckenstein
Annals of the New York Academy of Sciences|November 11, 2008
Differential response of neurotensin to methamphetamine self-administrationPaul S Frankel, Amanda J Hoonakker, Glen R Hanson
European Journal of Pharmacology|July 10, 2007
Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2Evan L Riddle, Glen R Hanson, Annette E Fleckenstein
Life Sciences|August 6, 2013
Bath salts and synthetic cathinones: an emerging designer drug phenomenonChristopher L German, Annette E Fleckenstein, Glen R Hanson
Pageof 10